Merck & Co., Inc. Derivative, Net Hedge Ineffectiveness Gain (Loss)
Merck & Co., Inc. (MRK) reported Derivative, Net Hedge Ineffectiveness Gain (Loss) of $5.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeNetHedgeIneffectivenessGainLoss · last filed 2018-02-27
- Merck & Co., Inc. derivative, net hedge ineffectiveness gain (loss) for the quarter ending 2017-12-31 was $2.00M.
- Merck & Co., Inc. derivative, net hedge ineffectiveness gain (loss) for the quarter ending 2017-09-30 was $1.00M, a 0.00% change year-over-year.
- Merck & Co., Inc. derivative, net hedge ineffectiveness gain (loss) for the quarter ending 2017-06-30 was $2.00M, a 100.00% increase year-over-year.
- Merck & Co., Inc. derivative, net hedge ineffectiveness gain (loss) for the quarter ending 2017-03-31 was $1.00M, a 66.67% decline year-over-year.
- Merck & Co., Inc. derivative, net hedge ineffectiveness gain (loss) for fiscal 2017 was $5.00M, a 400.00% increase from fiscal 2016.
- Merck & Co., Inc. derivative, net hedge ineffectiveness gain (loss) for fiscal 2016 was $1.00M, a 85.71% decline from fiscal 2015.
- Merck & Co., Inc. derivative, net hedge ineffectiveness gain (loss) for fiscal 2015 was $7.00M, a 133.33% increase from fiscal 2014.
- Merck & Co., Inc. derivative, net hedge ineffectiveness gain (loss) for fiscal 2014 was $3.00M, a 50.00% increase from fiscal 2013.
| Period end | Derivative, Net Hedge Ineffectiveness Gain (Loss) 3 month | Derivative, Net Hedge Ineffectiveness Gain (Loss) 6 month | Derivative, Net Hedge Ineffectiveness Gain (Loss) 6 month as first filed | Derivative, Net Hedge Ineffectiveness Gain (Loss) 9 month | Derivative, Net Hedge Ineffectiveness Gain (Loss) 12 month |
|---|---|---|---|---|---|
| 2017-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $3.00M derived: sum of 2 quarters · filed 2018-02-27 | $5.00M derived: sum of 3 quarters · filed 2018-02-27 | $5.00M 10-K · filed 2018-02-27 | |
| 2017-09-30 | $1.00M 10-Q · filed 2017-11-07 | $3.00M derived: sum of 2 quarters · filed 2017-11-07 | $3.00M 10-Q · filed 2017-11-07 | $1.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2017-06-30 | $2.00M 10-Q · filed 2017-08-08 | $3.00M 10-Q · filed 2017-08-08 | $0.00 derived: sum of 3 quarters · filed 2018-02-27 | $1.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2017-03-31 | $1.00M 10-Q · filed 2017-05-09 | -$2.00M derived: sum of 2 quarters · filed 2018-02-27 | -$1.00M derived: sum of 3 quarters · filed 2018-02-27 | $0.00 derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-12-31 | -$3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$2.00M derived: sum of 2 quarters · filed 2018-02-27 | -$1.00M derived: sum of 3 quarters · filed 2018-02-27 | $1.00M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $1.00M 10-Q · filed 2017-11-07 | $2.00M derived: sum of 2 quarters · filed 2017-11-07 | $4.00M 10-Q · filed 2017-11-07 | $6.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $1.00M 10-Q · filed 2017-08-08 | $4.00M 10-Q · filed 2017-08-08 | $5.00M derived: sum of 3 quarters · filed 2018-02-27 | $10.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | $3.00M 10-Q · filed 2017-05-09 | $4.00M derived: sum of 2 quarters · filed 2018-02-27 | $9.00M derived: sum of 3 quarters · filed 2018-02-27 | $8.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2015-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $6.00M derived: sum of 2 quarters · filed 2018-02-27 | $5.00M derived: sum of 3 quarters · filed 2018-02-27 | $7.00M 10-K · filed 2018-02-27 | |
| 2015-09-30 | $5.00M 10-Q · filed 2016-11-07 | $4.00M derived: sum of 2 quarters · filed 2016-11-07 | $6.00M 10-Q · filed 2016-11-07 | $7.00M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | -$1.00M 10-Q · filed 2016-08-08 | $2.00M 10-Q · filed 2016-08-08 | -$2.00M 10-Q · filed 2015-08-06 | $2.00M derived: sum of 3 quarters · filed 2017-02-28 | |
| 2015-03-31 | $3.00M 10-Q · filed 2016-05-09 | $3.00M derived: sum of 2 quarters · filed 2017-02-28 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $3.00M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $3.00M 10-Q · filed 2014-11-10 | ||||
| 2013-12-31 | $2.00M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |